(Sharecast News) - London stock markets closed in the red on Friday as sharp declines in airline, mining, and housebuilding stocks weighed on indices, with a lack of significant news and profit-taking ...
In contrast to the gloomy mood in Europe, US markets pushed higher. At the time of the London close, the Dow Jones Industrial Average was up 0.6%, the S&P 500 was 1.0% higher and the Nasdaq Composite ...
According to Bank of England data, net mortgage approvals for house purchases fell to 65,700 in November from 68,100 in October. However, approvals remained above their previous 12-month average of 60 ...
Griffin Mining Ltd, up 1.3% at 153.00 pence, 12-month range 86.50p-175.00p. The stock extends gains after a 3.4% rise on Thursday. The firm on Thursday said it received approval from the Emergency ...
(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.
London's FTSE 100 is set for a softer start on Friday, returning a fraction of the solid gain it made on the first trading day following the festive period. IG says futures indicate the FTSE 100 to ...
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.
(Alliance News) - Poolbeg Pharma PLC on Thursday said it was holding talks over an all-share combination with US-listed biopharmaceutical company Hookipa Pharma Inc. Under the proposed terms, ...
(Alliance News) - Emmerson PLC on Thursday said it has signed a deal with a specialist litigation funding firm to secure USD11.0 million in financing. The funding will go towards a dispute with the ...
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.
Chair Eric Sanderson said the sale of EMIC-1 is a "key milestone for progressing the wind-down of the company". The deal can allow the firm to "further deleverage its balance sheet" by trimming the ...
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday reported the opening of the first clinical site in its HG-CT-1 phase 1 trial. The London-based biotechnology company has so far focused on ...